is retatrutide glp-1 or glp 3 Eli Lilly just announced striking Phase results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% GLP-3 (R) - Triple GIP

The manufactures doses will only be produced by the manufacturer and may be in shortage, but compounded custom doses may continue even after the regulatory changes

Frequently Asked Questions How do recent FDA decisions affect my med spas ability to prescribe weight loss medications

If you are medically disqualified, you'll receive a refund for any unused months on your plan and your video visit will be free

Avoid high-intensity exercise until week 68 of treatment, as your body lacks glycogen reserves to fuel intense workouts during the adaptation phase

Tirzepatide is already approved as a glucose-lowering medication in patients with type 2 diabetes (T2D) and is currently being investigated in phase-3 trials for its weight loss benefits

At the same time, clinicians should reinforce the substantial benefits of treatment, including improved glycemic control, weight reduction, and cardiovascular protection